Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more and more cases linking them ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal ...

Global genital herpes treatment market will reach $5,051.8 million by 2032, growing by 4.7% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing ...

Doctors have begun noticing a trend among their colleagues: many have visibly shed pounds, and it's all thanks to drugs like Ozempic. In interviews with the New York Times, cardiologists are remarking ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

The potential impact of Trump's suspension of Foreign Corrupt Practices Act (FCPA) enforcement is significant, particularly ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

The S&P 500 and the Nasdaq ended higher while the Dow closed lower after a choppy trading session on Thursday, as investors sifted through earnings reports and awaited Amazon's results after the bell ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global pharmaceutical firm renowned for its innovative contributions to healthcare.

NEW YORK : The S&P 500 and the Nasdaq ended higher, while the Dow closed lower after a choppy trading session on Thursday, as investors sifted through earnings reports while awaiting Amazon’s results ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.